These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Pharmacotherapy of inflammatory bowel disease.
    Author: Gardner RC.
    Journal: Am J Hosp Pharm; 1976 Aug; 33(8):831-8. PubMed ID: 782236.
    Abstract:
    The etiology, pharmacotherapy and management of the two major types of inflammatory bowel disease--ulcerative colitis and Crohn's disease--are reviewed. Sulfasalazine and topical corticosteroids (i.e., hydrocortisone, hydrocortisone acetate or methylprednisolone acetate) are effective in many patients with mild distal ulcerative colitis. Maintenance sulfasalazine therapy significantly reduces the relapse rate in ulcerative colitis. Systemic corticosteroids (i.e., prednisone, prednisolone or methylprednisolone) have improved the survival rate of patients with moderate and severe ulcerative colitis. Antacids should be given regularly during high-dose steroid therapy to prevent gastritis. If oral steroids are ineffective, the use of parenteral corticosteroids (hydrocortisone sodium succinate or methylprednisolone sodium succinate) is suggested. Both sulfasalazine and corticosteroids appear to be effective in the treatment of Crohn's disease but require further investigation, however, if patients fail to respond to this therapy, oral corticosteriods, in low dosages, given concomitantly with azathioprine (currently under evaluation) is suggested.
    [Abstract] [Full Text] [Related] [New Search]